Fosamax Re-Titration After Stopping: How to Restart Alendronate Safely

What Happens to Bone During an Alendronate Drug Holiday

Drug holidays from alendronate are planned, not accidental pauses. Understanding what happens to bone during those months or years is the first step in deciding whether, and when, to re-enter treatment.

Residual Skeletal Activity After Stopping

Alendronate binds tightly to hydroxyapatite crystal surfaces in bone and is released slowly over years as bone remodeling occurs. Its skeletal half-life exceeds 10 years, meaning that even 3 to 5 years after the last dose, measurable bisphosphonate activity remains in cortical and trabecular compartments [1].

This residual activity is why a drug holiday is pharmacologically defensible for carefully selected patients. Bone turnover markers such as serum CTX (C-terminal telopeptide) typically remain suppressed for 12 to 18 months after stopping 70 mg weekly doses, and in some patients, suppression persists for 3+ years [2].

When BMD Loss Becomes Clinically Significant

Suppression does not last forever. A 2022 analysis of post-holiday bone mineral density trajectories found that lumbar spine BMD declined at a mean rate of 0.5 to 1.0% per year after stopping, with faster losses at the femoral neck in women older than 70 [3]. Patients who begin with T-scores close to -2.5 can cross the osteoporosis threshold within 2 to 3 years of stopping without monitoring.

The American Society for Bone and Mineral Research (ASBMR) task force states: "Patients at high fracture risk should not take a holiday from bisphosphonate therapy, and restart should be prompt if bone loss accelerates or fracture occurs during any holiday" [4].

Who Needs Re-Titration and When

Not every patient who stops alendronate needs to restart. Criteria-based reassessment, rather than a blanket policy, determines the right timing.

Indications for Restarting Alendronate

Restart alendronate when any one of these conditions is present:

• T-score drops to -2.5 or below at the spine, total hip, or femoral neck on a repeat DEXA scan after the drug holiday.
• A low-trauma (fragility) fracture occurs during the holiday, regardless of the DEXA result.
• The 10-year FRAX probability of major osteoporotic fracture returns above 20%, or hip fracture probability exceeds 3%, using the patient's current age, BMD, and clinical risk factors [5].
• Bone turnover markers (CTX, P1NP) rise above the premenopausal reference range on two consecutive measurements taken 3 months apart.

Patients Who Can Extend the Holiday

Patients who completed 5 years of oral alendronate with a baseline hip T-score above -2.5 and no incident fractures during treatment can remain off therapy and be re-evaluated by DEXA at 2 to 3 year intervals. The FLEX (Fracture Intervention Trial Long-Term Extension) trial followed 1,099 women originally randomized in FIT and found that those who discontinued after 5 years did not show significantly higher rates of non-vertebral fracture at 5 years compared to those who continued, provided their hip T-score was better than -2.5 at the time of stopping [6].

Pre-Restart Checklist

Before writing the prescription, confirm:

1. EGFR is at or above 35 mL/min/1.73 m². Alendronate is contraindicated below this threshold [7].
2. Serum calcium and 25-hydroxyvitamin D are within normal range. Correct deficiency before restarting; administering a bisphosphonate in a hypocalcemic patient risks worsening hypocalcemia.
3. Upper GI evaluation if the patient had esophageal or gastric symptoms during the original treatment course.
4. Dental review if any invasive dental procedures are planned. Medication-related osteonecrosis of the jaw (MRONJ), though rare with oral bisphosphonates, is a recognized risk, and the risk may theoretically persist given the long skeletal half-life [8].

The Re-Titration Protocol: Dose and Schedule

Re-titration after a drug holiday does not mean starting at a lower dose and stepping up. This is one of the most common misconceptions in osteoporosis management.

Starting Dose After a Holiday

The restart dose is identical to the original therapeutic dose: 70 mg orally once weekly for postmenopausal osteoporosis and male osteoporosis, or 10 mg orally once daily as the equally effective alternative [7]. There is no evidence supporting a lower initial dose on restart, and no Phase II or Phase III trial has evaluated a step-up protocol for alendronate re-initiation.

The daily 10 mg tablet is rarely chosen in modern practice because weekly dosing demonstrated equivalent antifracture efficacy with better GI tolerability in a randomized crossover comparison (N=242, P<0.001 for patient preference favoring weekly) [9]. Stick with the once-weekly 70 mg formulation unless daily dosing is clinically necessary.

Formulation Choices on Restart

| Formulation | Dose | Schedule | Notes | |---|---|---|---| | Alendronate 70 mg tablet | 70 mg | Once weekly | First-line; generic widely available | | Alendronate 70 mg/75 mL solution | 70 mg | Once weekly | Use if tablet dysphagia is a concern | | Alendronate 10 mg tablet | 10 mg | Daily | Reserve for patients who cannot tolerate weekly dosing for documented clinical reasons | | Alendronate 5 mg tablet | 5 mg | Daily | Approved for prevention, not treatment; do not use for re-treatment of established osteoporosis |

Administration Instructions That Cannot Be Skipped

The bioavailability of alendronate is approximately 0.7% under fasting conditions and drops to near zero if taken with food, coffee, or juice [7]. These instructions apply equally on day one of re-treatment as they did during the original course:

• Take on an empty stomach, first thing in the morning.
• Swallow with a full glass (6 to 8 oz, 180 to 240 mL) of plain water only.
• Do not lie down, eat, drink anything other than plain water, or take other medications for at least 30 minutes.
• Do not take at bedtime or before rising for the day.

Patients restarting after a long holiday often need a deliberate re-education session, since habits fade. A brief written instruction card at the time of the new prescription reduces administration errors and GI adverse events.

Monitoring After Restarting Alendronate

Restarting treatment without a monitoring plan defeats the purpose of the drug holiday.

DEXA Timing After Restart

Obtain a DEXA scan 1 to 2 years after restarting [4]. A 12-month scan is appropriate when:

• The restart followed a fragility fracture.
• The T-score at restart was at or below -2.5.
• The patient is on glucocorticoids (prednisone 5 mg/day or equivalent for 3 months or longer).

A 24-month scan is reasonable for patients restarting with a T-score between -1.5 and -2.4, no recent fracture, and stable clinical risk factors.

Bone Turnover Markers as an Interim Signal

DEXA takes 12 to 24 months to show statistically meaningful change because the least significant change for most machines is 2 to 4% at the lumbar spine. Bone turnover markers move faster.

Serum CTX should fall by 50 to 70% from the pre-treatment baseline within 3 to 6 months of restarting alendronate [10]. Measuring CTX at baseline (before the first tablet) and again at 3 months gives a concrete signal that the drug is being taken correctly and absorbed adequately. A CTX that fails to suppress by at least 30% at 3 months warrants a compliance and absorption review before attributing the response to drug failure.

When to Reassess the Choice of Agent

If BMD continues to fall despite 12 to 18 months of documented, correctly administered alendronate, consider:

• Switching to an IV bisphosphonate (zoledronic acid 5 mg once yearly) to remove the absorption and administration variables.
• Evaluating for secondary causes of osteoporosis (hyperparathyroidism, celiac disease, vitamin D malabsorption, hypogonadism).
• Consulting a bone metabolism specialist about transitioning to anabolic therapy (teriparatide, romosozumab) if the patient is at high fracture risk and has failed two bisphosphonate courses.

Fracture Risk Evidence Supporting Re-Treatment

FIT Trial Data

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) remains the bedrock evidence for alendronate's antifracture efficacy. In the hip fracture arm, 3 years of alendronate 5 mg/day (later 10 mg/day) produced a 47% relative risk reduction in hip fracture (1.1% vs. 2.2%, P<0.001) and a 55% reduction in clinical vertebral fractures compared to placebo [11]. These data inform the restart decision because they confirm that the drug works when taken correctly. The FIT population had a mean femoral neck T-score of -2.1, closely matching patients who present for re-treatment after a drug holiday.

FLEX Extension Data

FLEX (N=1,099, mean follow-up 10 years total including original FIT participation) demonstrated that 10 years of continuous alendronate reduced clinical vertebral fractures by 55% compared to stopping at 5 years [6]. This finding provides indirect support for restart in patients whose T-score has deteriorated, since the benefit of continued or restarted treatment on vertebral outcomes is maintained in the longer term.

Observational Data on Restart Timing

A large retrospective cohort study using U.S. Medicare claims (N=35,386 bisphosphonate users) found that patients who restarted within 24 months of stopping had a 23% lower risk of osteoporotic fracture over the subsequent 3 years compared to patients who never restarted, after adjustment for age, T-score, and prior fracture history [12]. Earlier restart correlated with better fracture outcomes, which argues against indefinitely extending the holiday in borderline-risk patients.

Special Populations: Dose Considerations

Glucocorticoid-Induced Osteoporosis

Patients taking prednisone 5 mg/day or more for 3 months or longer who restart alendronate should use the treatment dose (70 mg weekly or 10 mg daily), not the prevention dose (35 mg weekly or 5 mg daily), regardless of their baseline T-score [13]. The ACR 2022 guidelines on glucocorticoid-induced osteoporosis state that fracture risk in this population is disproportionately high for any given T-score because glucocorticoids impair osteoblast function independently of bone density [13].

Men With Osteoporosis

Alendronate is FDA-approved for osteoporosis in men at the same 70 mg weekly dose used in women [7]. A randomized trial of alendronate in men (N=241) showed 7.1% lumbar spine BMD gain at 2 years versus 1.8% for placebo (P<0.001) [14]. On restart after a drug holiday, the dose, schedule, and monitoring plan are identical to those used in women.

Older Adults (Age 75 and Above)

Renal function declines with age, making the pre-restart eGFR check especially important in patients older than 75. Beyond that, the clinical decision framework is the same. An analysis of the FIT trial population stratified by age found that women older than 70 derived at least as large an absolute fracture risk reduction as younger women, supporting restart in older adults who meet the criteria [11].

Practical Re-Titration Timeline: A Step-by-Step Framework

Below is a structured sequence for clinicians managing a restart. No step-up dosing is required; the focus is on timing, labs, and follow-up.

Week 0 (Restart Visit)

• Confirm restart indication (T-score, FRAX, fracture history, BTM rise).
• Check eGFR, serum calcium, 25-OH vitamin D. Correct deficiencies.
• Perform or order a baseline DEXA if the last scan was more than 18 months ago.
• Draw baseline CTX (morning, fasting sample preferred).
• Prescribe alendronate 70 mg once weekly. Review administration technique in detail.
• Prescribe calcium (total dietary plus supplemental: 1,200 mg/day for women older than 50) and vitamin D (800 to 1,000 IU/day minimum, adjust to maintain serum 25-OH vitamin D above 30 ng/mL) [5].

Month 3

• Repeat fasting morning CTX. Verify 50 to 70% suppression from baseline.
• Assess tolerability. Address upper GI symptoms if present; consider switching to oral solution or IV zoledronic acid if esophageal symptoms are intolerable.

Month 12 to 24

• Repeat DEXA (12 months for high-risk patients, 24 months for moderate-risk).
• Calculate T-score change and percent BMD change.
• Reassess FRAX using updated BMD.
• Document plan for continued treatment (typically another 3 to 5 year cycle) or re-evaluate need.

Year 5

• Formal reassessment of cumulative oral bisphosphonate exposure.
• Consider whether a second drug holiday is appropriate or whether switching to zoledronic acid, denosumab, or an anabolic agent is indicated.